Bonamy Holtak

The two doses of mRNA-1273 vaccine showed 94.1% efficacy at preventing COVID-19 illness including severe disease in persons 18 or older. Aside from transient local and systemic reactions, no safety…

Researchers have developed a “pilot-scale production of a purified inactivated SARS-CoV-2 virus vaccine candidate (PiCoVacc), which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats and non-human primates”. The induced antibodies neutralized…

Developing neutralising antibodies that target the SARS-CoV-2 Spike protein, has been highlighted as a potential strategy for an effective COVID-19 vaccine. Pre-clinical studies have demonstrated the ability to induce high…